MOH said it will provide an update when it is ready, with a decision expected to be made in 2026. Read more at ...

Alphyn, a clinical-stage dermatology company developing the first Multi-Target Therapeutics (R) drug platform, announced today that it has completed enrollment in its CLEAR-AD1 Phase 2b clinical trial ...

Lebrikizumab improved disease severity, skin clearance and symptom relief in children with moderate to severe atopic ...

Turn Therapeutics (NASDAQ:TTRX) executives outlined the company’s focus on inflammatory skin disease and provided updates on ...

TSW is a real but uncommon condition, when the skin develops a dependence on topical corticosteroids after prolonged use or ...

The campaign focuses on educating the one in 10 U.S. adults living with chronic hand eczema (CHE), particularly the one in three patients who have never heard the specific name of their condition.

Chronic Hand Eczema (CHE) is a highly debilitating inflammatory skin disease that affects approximately one in ten adults in ...

If none of your atopic dermatitis treatments have worked, you may be experiencing burnout (or treatment fatigue). Here's what ...

Managing atopic dermatitis (AD, also known as eczema) can be fraught with uncertainty about when the next flare-up will happen. You may go weeks or even months without any symptoms, only to have acute ...

Eli Lilly scored $408 million in U.S. sales of eczema treatment Ebglyss in its first full year on the market in 2025. | With ...

If you've seen a surge of videos about how to use a derma roller for hair growth on social media recently, you're not alone.

Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, ...